vs
CB Financial Services, Inc.（CBFV）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
CB Financial Services, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.5倍（$13.8M vs $9.1M），CB Financial Services, Inc.同比增速更快（19.9% vs -49.9%），CB Financial Services, Inc.自由现金流更多（$17.2M vs $1.6M），过去两年CB Financial Services, Inc.的营收复合增速更高（1.2% vs -6.7%）
CB银行是缅甸规模最大的商业银行之一，也是缅甸首家发行ATM卡与信用卡的银行。该银行由吴钦貌艾担任董事长、吴觉杜哥担任首席执行官，在缅甸全国拥有超过245家分支机构，是缅甸本土市场布局广泛的主流金融机构。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
CBFV vs PLX — 直观对比
营收规模更大
CBFV
是对方的1.5倍
$9.1M
营收增速更快
CBFV
高出69.8%
-49.9%
自由现金流更多
CBFV
多$15.5M
$1.6M
两年增速更快
CBFV
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.8M | $9.1M |
| 净利润 | — | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | 38.1% | -51.1% |
| 净利率 | — | -60.3% |
| 营收同比 | 19.9% | -49.9% |
| 净利润同比 | — | -184.8% |
| 每股收益（稀释后） | $0.90 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBFVPLX
| Q4 25 | $13.8M | $9.1M | ||
| Q3 25 | $2.4M | $17.9M | ||
| Q2 25 | $13.5M | $15.7M | ||
| Q1 25 | $12.1M | $10.1M | ||
| Q4 24 | $13.2M | $18.2M | ||
| Q3 24 | $12.7M | $18.0M | ||
| Q2 24 | $12.2M | $13.5M | ||
| Q1 24 | $13.5M | — |
净利润CBFVPLX
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $-5.7M | $2.4M | ||
| Q2 25 | $3.9M | $164.0K | ||
| Q1 25 | $1.9M | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $3.2M | $3.2M | ||
| Q2 24 | $2.6M | $-2.2M | ||
| Q1 24 | $4.2M | — |
毛利率CBFVPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率CBFVPLX
| Q4 25 | 38.1% | -51.1% | ||
| Q3 25 | -289.8% | 11.9% | ||
| Q2 25 | 35.0% | 7.5% | ||
| Q1 25 | 19.3% | -41.0% | ||
| Q4 24 | 23.1% | 39.6% | ||
| Q3 24 | 31.2% | 22.2% | ||
| Q2 24 | 26.4% | -18.0% | ||
| Q1 24 | 37.9% | — |
净利率CBFVPLX
| Q4 25 | — | -60.3% | ||
| Q3 25 | -235.2% | 13.2% | ||
| Q2 25 | 29.3% | 1.0% | ||
| Q1 25 | 15.8% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | 25.3% | 18.0% | ||
| Q2 24 | 21.8% | -16.4% | ||
| Q1 24 | 31.1% | — |
每股收益（稀释后）CBFVPLX
| Q4 25 | $0.90 | $-0.06 | ||
| Q3 25 | $-1.07 | $0.03 | ||
| Q2 25 | $0.74 | $0.00 | ||
| Q1 25 | $0.35 | $-0.05 | ||
| Q4 24 | $0.45 | $0.10 | ||
| Q3 24 | $0.60 | $0.03 | ||
| Q2 24 | $0.51 | $-0.03 | ||
| Q1 24 | $0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.7M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $157.5M | $48.2M |
| 总资产 | $1.5B | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBFVPLX
| Q4 25 | $31.7M | $14.7M | ||
| Q3 25 | $55.9M | $13.6M | ||
| Q2 25 | $64.5M | $17.9M | ||
| Q1 25 | $61.3M | $19.5M | ||
| Q4 24 | $49.6M | $19.8M | ||
| Q3 24 | $147.3M | $27.4M | ||
| Q2 24 | $142.6M | $23.4M | ||
| Q1 24 | $73.7M | — |
股东权益CBFVPLX
| Q4 25 | $157.5M | $48.2M | ||
| Q3 25 | $152.5M | $52.9M | ||
| Q2 25 | $148.4M | $49.9M | ||
| Q1 25 | $148.3M | $45.2M | ||
| Q4 24 | $147.4M | $43.2M | ||
| Q3 24 | $149.1M | $32.4M | ||
| Q2 24 | $142.9M | $28.6M | ||
| Q1 24 | $141.6M | — |
总资产CBFVPLX
| Q4 25 | $1.5B | $82.3M | ||
| Q3 25 | $1.5B | $82.3M | ||
| Q2 25 | $1.5B | $78.5M | ||
| Q1 25 | $1.5B | $73.9M | ||
| Q4 24 | $1.5B | $73.4M | ||
| Q3 24 | $1.6B | $61.6M | ||
| Q2 24 | $1.6B | $91.5M | ||
| Q1 24 | $1.5B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.8M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $17.2M | $1.6M |
| 自由现金流率自由现金流/营收 | 124.1% | 17.8% |
| 资本支出强度资本支出/营收 | 4.7% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $29.5M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流CBFVPLX
| Q4 25 | $17.8M | $2.0M | ||
| Q3 25 | $4.6M | $-3.7M | ||
| Q2 25 | $4.1M | $-5.2M | ||
| Q1 25 | $4.0M | $-5.1M | ||
| Q4 24 | $6.8M | $4.0M | ||
| Q3 24 | $3.1M | $4.1M | ||
| Q2 24 | $-1.2M | $-3.6M | ||
| Q1 24 | $3.3M | — |
自由现金流CBFVPLX
| Q4 25 | $17.2M | $1.6M | ||
| Q3 25 | $4.5M | $-4.2M | ||
| Q2 25 | $3.9M | $-5.7M | ||
| Q1 25 | $3.9M | $-5.4M | ||
| Q4 24 | $3.4M | $3.6M | ||
| Q3 24 | $2.2M | $4.0M | ||
| Q2 24 | $-2.4M | $-3.8M | ||
| Q1 24 | $2.3M | — |
自由现金流率CBFVPLX
| Q4 25 | 124.1% | 17.8% | ||
| Q3 25 | 186.5% | -23.7% | ||
| Q2 25 | 28.8% | -36.2% | ||
| Q1 25 | 32.5% | -53.0% | ||
| Q4 24 | 26.0% | 19.6% | ||
| Q3 24 | 17.4% | 22.4% | ||
| Q2 24 | -19.6% | -28.1% | ||
| Q1 24 | 17.0% | — |
资本支出强度CBFVPLX
| Q4 25 | 4.7% | 4.4% | ||
| Q3 25 | 4.3% | 2.8% | ||
| Q2 25 | 1.9% | 2.8% | ||
| Q1 25 | 0.8% | 3.0% | ||
| Q4 24 | 25.1% | 2.3% | ||
| Q3 24 | 6.7% | 0.5% | ||
| Q2 24 | 10.0% | 1.3% | ||
| Q1 24 | 7.2% | — |
现金转化率CBFVPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | 1.05× | -31.91× | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | 0.95× | 1.27× | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBFV
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
